• Mentari Therapeutics targets a first-quarter 2027 regulatory filing for migraine candidate MT-002, with Phase 1 data expected by year-end.
• MT-001 Phase 1 data are expected in mid-2027, followed by initial Phase 2 proof-of-concept data in migraine patients in 2028.
• The five-program antibody pipeline includes MT-002, which targets both PACAP and CGRP to potentially improve migraine prevention.
• About $490 million raised to date supports development beyond key anticipated milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentari Therapeutics Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.